Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) EBITDA (2016 - 2025)

Historic EBITDA for Nephros (NEPH) over the last 17 years, with Q3 2025 value amounting to $314000.0.

  • Nephros' EBITDA rose 5242.72% to $314000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 25471.09%. This contributed to the annual value of $6000.0 for FY2024, which is 10038.1% up from last year.
  • As of Q3 2025, Nephros' EBITDA stood at $314000.0, which was up 5242.72% from $248000.0 recorded in Q2 2025.
  • Over the past 5 years, Nephros' EBITDA peaked at $566000.0 during Q1 2025, and registered a low of -$3.2 million during Q3 2022.
  • Over the past 5 years, Nephros' median EBITDA value was -$433000.0 (recorded in 2023), while the average stood at -$627526.3.
  • In the last 5 years, Nephros' EBITDA crashed by 23770.76% in 2022 and then skyrocketed by 43491.12% in 2025.
  • Quarter analysis of 5 years shows Nephros' EBITDA stood at -$1.1 million in 2021, then rose by 15.93% to -$929000.0 in 2022, then grew by 29.6% to -$654000.0 in 2023, then skyrocketed by 148.47% to $317000.0 in 2024, then dropped by 0.95% to $314000.0 in 2025.
  • Its EBITDA was $314000.0 in Q3 2025, compared to $248000.0 in Q2 2025 and $566000.0 in Q1 2025.